Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) receiving open-label Sorafenib post-progression on the phase III decision trial
Paschke, R, Schlumberger, M, Nutting, C, Jarzab, B, Elisei, R, Siena, S, Bastholt, L, de la Fouchardiere, C, Pacini, F, Shong, YK, Sherman, SI, Smit, J, Kappeler, C, Molnar, I, Brose, MF
Published in Experimental and Clinical Endocrinology & Diabetes (12.03.2015)
Published in Experimental and Clinical Endocrinology & Diabetes (12.03.2015)
Get full text
Conference Proceeding
Prognostic and predictive factors correlated with treatment outcomes for radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) patients receiving Sorafenib or placebo on the phase III decision trial
Paschke, R, Schlumberger, M, Elisei, R, Pacini, F, Jarzab, B, Giannetta, L, Bastholt, L, de la Fouchardiere, C, Worden, FP, Shong, YK, Smit, J, Kappeler, C, Molnar, I, Brose, MF
Published in Experimental and Clinical Endocrinology & Diabetes (12.03.2015)
Published in Experimental and Clinical Endocrinology & Diabetes (12.03.2015)
Get full text
Conference Proceeding